Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering

This study has been completed.
Texas Heart Institute (Wafic Said Molecular Cardiology Research Lab)
Astrazeneca (direct)
InfraReDx (indirect)
Information provided by (Responsible Party):
Annapoorna Kini, Icahn School of Medicine at Mount Sinai Identifier:
First received: April 5, 2013
Last updated: August 9, 2016
Last verified: August 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2015
  Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)